Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
Lenvatinib was non‐inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma, and PD‐1 antibody was effective and tolerable in patients with advanced hepatocellular carcinoma. No study has compared the efficacy and safety of lenvatinib plus PD‐1 antibody and lenvatinib alone. Thus, the investigators carried out this prospective randomized control study to find out it.
Epistemonikos ID: 71bd2e44df0aac4f305f6d42a7a0a537824fc92e
First added on: May 21, 2024